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Background: To evaluate the efficacy of hypofractionated radiotherapy (HyRT) with or without image guided
radiotherapy (IGRT) in intermediate risk prostate cancer.
Methods: 105 patients were treated with HyRT, 43,8 Gy and 54,75 Gy were delivered to the seminal vescicles and
to the prostate, respectively; 3,65 Gy/fraction three times weekly. All patients underwent 9 months hormonal
therapy. Patient position was verified with daily kV cone beam CT in 69 patients (IGRT group). Acute and late
toxicities were evaluated according to RTOG scale. Biochemical relapse was defined using PSA nadir + 2 ng/mL.
The data were prospectively collected and retrospectively analyzed to evaluate the efficacy of IGRT.
Results: After a median follow-up of 31 months the actuarial 3-year bNED was 93,7%. During RT, 10.5% and 7.6% of
patients developed ≥Grade 2 rectal and urinary toxicities, respectively. The cumulative incidence of ≥Grade 2 late
rectal and urinary toxicities at 3 years were 6,9%, and 10,8%, respectively. The incidence of ≥Grade 2 late rectal
toxicities was significant reduced in the IGRT group (1,6% vs. 14,5%, p=0,021). Two patients developed Grade 3
urethral obstruction and one patient developed grade 3 rectal bleeding.
Conclusions: HyRT represents a well-tolerated treatment able to achieve a high bNED. The use of daily IGRT is
beneficial for reducing the incidence of late toxicities.
Keywords: Intermediate-risk prostate cancer, Hypofractionated radiotherapy, IGRT, 3D-CRTBackground
External Beam Radiotherapy (RT) is one of the thera-
peutic options for treating prostate cancer. The use of
high dose RT with a conventional fractionation delivered
conformally to spare as much normal tissue as possible,
results in a significant biochemical control with accep-
table toxicities [1].
In the past decade hypofractionated radiotherapy
(HyRT) has been proposed as an alternative to conven-
tional fractionation. Unlike most tumors, the estimated
α/β ratio of prostate cancer is about 1.5 Gy, showing
lower value compared to the α/β of surrounding tissues* Correspondence: stefano.bracci@yahoo.it
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reproduction in any medium, provided the or(e.g. rectum) [2]. Prostate cancer, because of its intrinsic
slow proliferation, would be more sensitive to fraction-
ations than nearby late-responding tissues. According to
the Linear-Quadratic Model (LQM), the use of fewer and
larger fractions of radiation instead of the conventional
daily fractions of 2 Gy, would lead to an expected thera-
peutic advantage [3]. Moreover, HyRT is convenient for
patients since the overall treatment time is reduced of
several weeks depending on the higher dose per fraction,
as well as for costs reduction of the health care system.
Randomized phase 3 trials comparing HyRT vs. con-
ventional RT were carried out in late 1990s, but results
are not conclusive because total doses used both in the
control arm (64–66 Gy) and in the hypofractionated arm
(biological equivalent dose of 62–67 Gy) are consideredl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Patients’ characteristics
Characteristics Non IGRT IGRT Total p
value*(n=36) (n=69) (n=105)
n. % n. % n. %
Age
<75 15 41,7 40 58 55 52,4 0,112
≥75 21 58,3 29 42 50 47,6
PSA at the diagnosis (ng/mL)
0.1- 10 22 61,1 33 47,8 55 52,4 0,196
10.1 -19.9 14 38,9 36 52,2 50 47,6
Gleason Score
3+3 8 22,2 25 36,2 33 31,4 0,340
3+4 19 52,8 30 43,5 49 46,7
4+3 9 25 14 20,3 23 21,9
Clinical Stage
T1c 6 16,7 1 1,4 7 6,7 0.011
T2a 13 36,1 20 29 33 31,4
T2b 8 22,2 28 40,6 36 34,3
T2c 9 25 20 29 29 27,6
Hormonal Therapy
Anti-androgen 23 63,9 53 49,9 76 72,4 0.160
GnRH agonist 13 36,1 16 19,1 29 27,6
*Chi-square test.
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on clinical outcome of the RTOG 9406 trial, concluded
that dose-escalated 3D-CRT yields favorable outcomes
for localized prostate cancer [6]. In the past decade
differents fractionations have been explored in several
randomized and non-randomized trials with good
biochemical control and with acceptable acute and late
toxicity profile [7-9]. Furthermore, the progress in radio-
therapy techniques capable to spare healthy tissues
allowing a dose-escalation such as intensity modulated
RT (IMRT), stereotactic body RT (SBRT) or the use of
image-guided RT (IGRT) would probably lead to a better
clinical outcome [10-15].
To assess this issue, in 2007 we started a study using a
novel HyRT regimen with or without IGRT for intermedi-
ate risk prostate carcinoma. A preliminary report regard-
ing acute toxicity on 62 patients enrolled was previously
published [16]. In the present paper, the authors assessed
acute and late toxicity rates and provide survivals data in a
cohort of 105 intermediate risk patients. Subgroups’ ana-
lysis was also performed to evaluate any difference related
to the use or not of daily IGRT in terms of toxicity or
biochemical no evidence of disease (bNED).
Methods
Patients’ characteristics
Between March 2007 and June 2011, 105 consecutive
patients affected by intermediate risk prostate cancer were
prospectively enrolled. Under an IRB-approved protocol
the data were prospectively collected and retrospectively
analyzed to evaluate the efficacy of IGRT in terms of toxi-
cities and bNED. Written consent was obtained from all
patient. All patients had histologically confirmed diagnosis
and Gleason Score definition using transrectal ultrasound
(TRUS) guided biopsies. The pre-treatment evaluation
included patients’ complete history, physical examination
with digital rectal examination (DRE), blood tests including
PSA level, total body computed tomography (CT) scan
with iodine-based contrast and 99mTc bone scan. TRUS
was employed for local staging in the early group of
patients included (n=36, non-IGRT group), while multi-
parametric magnetic resonance imaging (MRI) of the pelvis
including diffusion-weighted imaging (DWI) and dynamic
contrast-enhanced study (DCE-MRI) was obtained in the
following group of patients (n=69, IGRT group).
According to the National Comprehensive Cancer
Network (NCCN) guidelines, intermediate risk group
includes patients with any clinical T2b–T2c prostate
cancer, Gleason Score equal to 7 or pre-treatment PSA
value ranging from 10 to 20 ng/mL [17].
Simulation and treatment
Prior to simulation, patients were educated to empty the
rectum and fill the bladder. All patients were immobilizedin the supine position with feet fixation. A pre-treatment
CT planning with 2.5 mm slices from the anal verge to
the L5–S1 interface was performed. Planning CT images
were fused with the multiparametric MRI to better deli-
neate the Clinical Target Volume (CTV) in the IGRT
group (n=69). The CTV1 included the prostate plus sem-
inal vesicles (SSVV) and the CTV2 the prostate alone.
Planning Target Volumes (PTV1 and PTV2, respectively)
were generated adding a 8 mm margin in all directions
except in the posterior direction where a 6 mm expansion
was adopted in the non-IGRT group (n=36). A 5 mm
expansion in all direction was used for the IGRT group.
Indeed, the use of daily CBCT permit to reduce set-up
errors as well the internal margin due to the interfraction
motion of the prostate. The margin of 5 mm has been
chosen to encompass the intrafraction movement also
taking into account the deformation of the target as well
as of the organ at risk (i.e. bladder and rectum) during the
treatment.
The whole rectum from the anus to the sigmoid flexure,
bladder, femoral heads and penile bulb were contoured as
organs at risk.
A 3D conformal radiotherapy (3D-CRT) plan on the
Eclipse planning system (Varian, Palo Alto, CA) was
performed using 5 coplanar fields. Treatment was deli-
vered by a linear accelerator using 15 MV photons. Thus
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fraction) and the PTV2 received 54.75 Gy in 15 fractions,
three times a week. According to the LQM this RT regi-
men is biologically equivalent to 80.5 Gy in 2 Gy fractions
assuming a α/β ratio of 1.5 Gy. This regimen is also
equivalent to 72.8 Gy in 2 Gy fractions assuming a α/β
ratio of 3 Gy for late responding tissue. The overall treat-
ment time has been chosen based on studies on acute
mucosal toxicity in head and neck cancers showing that a
BED10 over 60 Gy may be associated with a higher acute
toxicity rate [2]. Thus, with the aim to maintain the acute
toxicity rate and the consequential late damage low, we
decided not to shorten below 5 weeks the overall treat-
ment time. [18]. Dose–volume constraints were as follows:
V45<35% and V52<25% for the rectum; V40<50% for the
bladder.
Patient position was verified using electronic portal
imaging device (EPID) in the non-IGRT group, while the
IGRT group underwent daily kV cone-beam CT (CBCT).
Neoadjuvant, concomitant and adjuvant hormonal
therapy (HT) was started 3 months before RT. The HT
consisted in anti-androgen or LHRH-analogue accordingFigure 1 Overall survival, disease-specific survival and biochemical noto the treating physician’s preference and was adminis-
tered to all patients.
Toxicity and follow-up
Follow up was performed every 3 months for the first
year and every 6 months afterwards. Toxicities were pro-
spectively assessed according to the Radiation Therapy
Oncology Group (RTOG) scale for acute and late adverse
effects at each follow-up [19]. In general, the occurrence
of symptoms not requiring medications or an increased in
magnitude of baseline symptoms were considered as
Grade 1 toxicities. Grade 2 toxicities were considered as
the occurrence of symptoms requiring new medications
(e.g. antidiarrheal drugs) or increase of previously pre-
scribed medication or symptoms requiring a single surgi-
cal intervention (i.e. single laser coagulation). Grade 3
toxicities were defined as the occurrence of symptoms
requiring surgery (i.e. TURP or permanent catheter or
bleeding requiring ≥2 laser coagulation). Late toxicities
were defined as occurring after 90 days from the comple-
tion of treatment. Erectile dysfunction was also evaluated
using the following question from the Sexual Adjustmentevidence of disease.
Table 3 Prevalence of toxicities according to RTOG scale
Follow-up
(months)
During RT 3 6 9 12 18 24
Toxicity Grade % % % % % % %
Bowel frequency 0 87 99 98 98 98 100 98
1 8 1 2 2 2 0 2
2 5 0 0 0 0 0 0
Proctitis 0 95 100 100 100 99 99 100
1 4 0 0 0 1 1 0
2 1 0 0 0 0 0 0
Rectal bleeding 0 92 96 96 93 94 94 91
1 5 3 2 4 3 3 7
2 3 1 1 2 2 2 0
3 0 0 1 1 1 1 2
Hematuria 0 99 97 98 98 97 96 95
1 1 3 2 2 3 4 4
2 0 0 0 0 0 0 1
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an erection?” at baseline, 3 months after RT and 1 year
after HT. The five levels of response were: always, almost
always, sometimes, almost never, never, not applicable/not
answer [20].
Statistical analysis
The biochemical failure was defined as the PSA nadir +
2 ng/mL according to the Phoenix criteria [21]. Overall
survival (OS), disease specific survival (DSS), bNED and
the cumulative incidence of ≥ Grade 2 late toxicity were
calculated to the event using the Kaplan–Meier method.
In the subgroups’ analysis acute toxicities between the
IGRT and non-IGRT series were compared using the
chi-square test. Differences in bNED as well the cumula-
tive incidence of ≥ Grade2 late toxicities between the
two groups were evaluated with log-rank test. Statistical
analyses were performed using SPSS statistical software
package version 13.0 (SPSS, Inc., Chicago, IL). A p-value
of less than 0.05 was considered to be statistically
significant.
Results
Patients’ characteristics and survivals
Median age at diagnosis was 74 years (range, 55–88 years).
Thirty-three patients had Gleason 6 (3+3) and 7 patients
presented with T1c clinical stage. Median PSA level at
diagnosis was 10 ng/mL (range, 2–19,9). Patients’ charac-
teristics are summarized in Table 1.
After a median follow-up of 31 months (range, 6–
64 months), the actuarial 3-year BFS was 93,7% (Figure 1).
The median follow-up was 50 months (range, 7–
64 months) and 25 months (range, 6–43 months) for non-
IGRT and IGRT patients, respectively. Five patients deve-
loped biochemical failure: 3 patients were found to have
metastasis to loco-regional lymph nodes and 2 patients
had bone metastasis. Subsequently, all these patients
(n=5) were submitted to total Androgen Deprivation
Therapy (ADT). Patients with regional lymph nodesTable 2 Comparison of acute rectal and urinary toxicities
in the no IGRT group vs. IGRT group









n. % n. % n. % n. %
during RT
G1 8 22.2 8 11.6 0.105 18 50 32 46.4 0.724
≥G2 2 5.6 9 13 0.234 3 8.3 5 7.2 0.842
3 months FU
G1 2 5.6 2 2.9 0.5 13 36.1 20 29 0.455
≥G2 0 0 1 1.4 0.468 1 2.8 2 2.9 0.972
* Chi-square test.received salvage radiation therapy based on 18FCholine-
PET/TC. Patients with bone metastasis received palliative
radiation treatment. Then, PSA levels normalization was
obtained in 3 patients (node metastasis: 2 patients; bone
metastasis: 1 patient). One patient with lymph-node
metastasis did not respond to ADT plus RT and under-
went taxane-based chemotherapy that is still ongoing. The
other patient with bone metastasis died because of
systemic disease progression. Six patients died from
intecurrent disease without evidence of prostate cancer.
The 3-year OS was 95% and the 3-years DSS 98,2%
(Figure 1). No differences were found in BFS between the
two groups of patients (91,3% vs. 94,3%; p=0,413).
Acute toxicities
During RT, 15.2% of the patients developed Grade 1 GI
toxicity and 10.5% developed ≥ Grade 2 GI toxicity. At
3 months after RT, 4 patients had Grade 1 GI toxicities
and only 1 patient had a Grade 2 proctitis. Acute GUDysuria 0 79 89 95 93 98 97 96
1 20 11 5 7 2 3 4
2 1 0 0 0 0 0 0
Urinary frequency 0 79 94 93 95 93 96 96
1 18 5 6 5 6 4 4
2 3 1 1 0 1 0 0
Retention 0 89 97 95 96 97 96 96
1 10 2 3 1 1 2 0
2 1 1 0 1 0 1 2
3 0 0 2 2 2 1 2
Incontinence 0 87 80 85 90 90 87 87
1 8 18 14 9 9 10 11
2 5 2 1 1 1 3 2
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rienced Grade 1 toxicities and 7.6% experienced ≥ Grade
2 toxicities. At 3 months after RT, 31.4% had Grade 1 GU
toxicities and 2.9% had ≥ Grade 2 GU toxicities. None had
grade 3–4 acute toxicities (Table 2).Late toxicities
A total of 10 patients (9,5%) developed ≥ Grade 2 GU
toxicities and 6 patients (5,7%) developed ≥ Grade 2 GI
toxicities. The prevalence of GI and GU toxicities accor-
ding to RTOG scale are shown in Table 3. The cumula-
tive incidence of ≥ Grade 2 GI toxicities at 3 years was
6,9%, while the cumulative incidence of ≥ Grade 2 GU
toxicities at 3 years was 10,8% (Figure 2). Two patients
developed Grade 3 urethral obstruction at 6 months
from RT completion (1 permanent catheter and 1
TURP). One patient developed grade 3 rectal bleeding at
6 months that required repeated argon plasma coagula-
tion. None developed Grade 4 toxicity. The cumulative
incidence of ≥ Grade 2 GI toxicities was significant
reduced in the IGRT group (1,6% vs. 14,5%, p=0,021) as
well as the cumulative incidence of both GI and GU ≥
Grade 2 toxicities (28,9% vs. 8,1%, p=0,013) (Figure 3b
and c). On the other hand, the cumulative incidence
of ≥ Grade 2 GU toxicities resulted not statisticallyFigure 2 Cumulative incidence of rectal, urinary and rectal + urinarydifferent in the two groups (6,5% vs. 17,1%, p=0,127)
(Figure 3a).
Sexual function
At baseline, 46.6% was always (21.9%) or almost always
(24.8%) able to have an erection, while at the first follow-
up, only the 10.5% of patients was always (1.9%) or almost
always (8.6%) able to have an erection. After 1 year from
the end of HT there was a partial recovery of sexual func-
tion (17.1% always or almost always) (Table 4).
Discussion
Hypofractionated radiotherapy represents an attractive
therapeutic option for tumors with low proliferation
grade such as prostate cancer. The difference in α/β
ratio between the tumor itself and surrounding normal
tissues may lead to a therapeutic gain as well as an
advantage for the patient and the health care system
because the reduced overall duration of the treatment.
In the last decade, several randomized trial compared
HyRT vs. conventional RT showing good toxicity rates
and local control but only in a few studies was an
adequate dose delivered [4,5,7,10].
In particular, Lukka et al. delivered 66 Gy in 33 fractions
(conventional RT) vs. 52.5 Gy in 20 fractions over 28 days
(HyRT), while Yeoh et al. compared hypofractionated≥ Grade 2 late toxicities.
Figure 3 Comparison of (a) urinary, (b) rectal and (c) rectal + urinary ≥ Grade 2 late toxicities in the non-IGRT and IGRT patients.
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conventionally fractionated RT (64 Gy in 32 fractions
within 6.5 weeks) [4,5].
Dearnaley et al. compared a conventional schedule of
74 Gy in 37 fractions with two hypofractionated high-
dose intensity-modulated schedules with a total dose
60 Gy or 57 Gy, delivered in 20 or 19 fractions of 3 Gy
per fraction, respectively [10]. All patients were also sub-
mitted to receive ADT for 4–6 months. The cumulative
rates of late GI and GU toxicities ≥ Grade 2 showed not
statistically significant differences between the three
groups while survival analysis was not reported.
Arcangeli et al. randomized 168 high-risk prostate
cancer patients to receive HyRT (62 Gy in 20 fractions,
4 fractions/week) or conventionally fractionated (80 Gy
in 40 fractions) three-dimensional conformal radiother-
apy to the prostate and seminal vesicles [7]. All patients
were also submitted to 9 months-ADT started 2 months
before RT. The reported ≥ Grade 2 GI and GU late
toxicities were similar in both groups, while the 4-yearTable 4 Sexual function at baseline, 3 months after RT
and 1 year after HT
Response Sexual function*
At baseline 3 months after RT 1 year after HT
n. % n. % n. %
Always 23 21.9 2 1.9 10 9.6
Almost always 26 24.8 9 8.6 8 7.6
Sometimes 21 20 15 14.3 20 19
Almost never 12 11.4 24 22.9 25 23.8
Never 11 10.5 43 40.9 21 20
Not applicable
or not answer
12 11.4 12 11.4 21 20
*Responses were to the question, “When sexually excited, are you able to get
an erection?”actuarial freedom from biochemical failure was signifi-
cantly different for patients treated with HyRT vs. conven-
tional fractionation (82% vs. 60%, respectively; p = 0.004).
The use of HyRT in prostate cancer patients has also
been investigated in several recent phase II studies that
demonstrated good biochemical control rates depending
on risk stratification and acceptable toxicities (≥ Grade 2
GU and GI late toxicities ranging from 3% to 25%)
[8,9,11-13,22]. Therefore, further randomized studies are
needed to confirm these data. In the present study, 5.7%
patients experienced ≥ Grade 2 GI toxicity and 9.5% pa-
tients had ≥ Grade 2 GU toxicity. Our results are com-
parable to those reported in the literature.
Zelefsky et al. found that high-dose IGRT is associated
with a low rate of late urinary toxicity and with an im-
provement in biochemical tumor control among high-
risk patients [23]. Differently, in our study the use of
IGRT was associated to a decreased late GI toxicity and
combined late GI plus GU toxicities. Such different re-
sults obtained by Zelefsky et al. can be explained by the
use of IMRT instead of 3D-CRT, a technique able to
spare the bladder neck that is responsible of late GU
toxicities after radiotherapy. On the contrary, the reduc-
tion in late GI toxicities we observed are possibly due to
several factors such as: the role of MRI during the plan-
ning that reduced the CTV, the reduced PTV margin,
and the daily CBCT that decreased set-up errors. Acute
toxicity rates were similar in both groups, even if a trend
of significance for better outcome was found regarding
the incidence of acute GI toxicity in favor of IGRT.
The association of ADT to HyRT is still an open ques-
tion. A preliminary report of the French trial GETUG 14
regarding patients affected by intermediate-risk cancer
treated with dose escalated RT vs. dose escalated RT plus
short course ADT showed a statistically significant in-
creased 3-year biochemical progression-free survival; no
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bined biochemical and local tumor control [24]. A retro-
spective study by Zumsteg et al. demonstrated that
short-term ADT improves prostate specific antigen
recurrence-free survival, distant metastasis and prostate
cancer specific mortality in patients with intermediate-
risk cancer undergoing dose-escalated external beam
radiation therapy [25]. Despite the fact that the short
course ADT is useful for dose escalated RT in inter-
mediate risk patients, the association with HyRT is still
controversial. A recent report by Faria et al. showed a
5-year actuarial biochemical recurrence free survival of
95.4% in intermediate-risk prostate cancer patients
treated with HyRT alone (total dose of 66 Gy in 22
fractions) after a median follow-up of 51 months [9].
The authors explained these results with a short overall
treatment time (30.5 days) and the high biologically
equivalent dose delivered. Similarly to Arcangeli et al. in
our study all patients underwent 9 months ADT
reaching a 3-years bNED of 93.7%. The results achieved
by Faria et al. are similar to those obtained in our study
suggesting that HT may be avoided when HyRT is deli-
vered since HT don’t seems to improve the results of
HyRT in intermediate-risk prostate cancer patients. Fur-
thermore, Kupelian et al. found that the use of hormonal
therapy before or after HyRT (70 Gy at 2.5 Gy per frac-
tion) was an independent predictor of a worse outcome
[13]. However, to determine the exact role of HT in the
era of HyRT in intermediate-risk prostate cancer rando-
mized trials are needed.
The strength of this paper is that a novel HyRT schedule
was examined in 105 patients affected by intermediate-
risk prostate cancer. The majority of studies on prostate
cancer includes different categories of risk making the
results not generalizable. Indeed, it should be taken into
account that intermediate-risk prostate cancer itself would
represent a clinically non-uniform group of disease cha-
racterized by a wide range of clinical behavior [26].
On the other hand, there are several limits of this
study including the low median follow-up and the diffe-
rent RT technique used. Moreover, the study was un-
powered to detect differences in terms of acute toxicities
between the two groups of patients, probably due to the
small number of patients treated without IGRT. Despite
these limits we found a clearly advantage of using daily
IGRT in HyRT in terms of reduced ≥ Grade 2 late
toxicities.
Conclusions
In conclusion, the HyRT schedule represents a well-
tolerated treatment with acceptable rates of both acute
and late toxicity, able to achieve a high bNED in
intermediate-risk prostate cancer; but a longer follow-up
is needed. The use of daily IGRT is beneficial for reducingthe incidence of late toxicities but further studies are
required to confirm these results.
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